UC Riverside May have Found a Way for Restricting Spread of Ovarian Cancer
A pair of researchers from UC Riverside have claimed discovery of a mechanism, which would stop ovarian cancer from spreading further. Ovarian cancer has been the deadliest cancer for women. Oleg Kim and Mark Alber, along with their team of researchers have published their study in Oncology Times. The study published details how a monoclonal antibody, known as GC-4, was utilized for blocking a protein that was responsible for allowing the ovarian cancer cells in latching on to other cells, and penetrate into them.
Alber and Kim’s Involvement in Medical Research Implies Cross-Disciplinary Push by Universities for Addressing a Critical Issue
Kim and Alber, both arrived at the UCR in the previous year, are planning to work in Duarte, with City of Hope, in order to perform studies on human patients. This might hopefully lead to the development of an effective drug for treatment of ovarian cancer. A surprising fact is that both Kim and Alber work in the mathematics department of UCR, and neither of them is a biologist. Their involvement in the medical research implies some of the universities’ cross-disciplinary push over the past decade, wherein researchers of different expertise combine their talents for addressing an important issue.
According to Alber, beyond mathematics and calculus lies mathematical modelling, and these researchers observe the biological process by continuously conversing with medical doctors and biologists. Then further gaining knowledge about imperative aspects, Alber and his team utilize the information for depicting and predicting the operation of biological systems. In case of the study of ovarian cancer, the researchers modeled the behavior related to two types of a protein, named cadherin, including the interaction process of cells with abdominal tissue. One type of this protein, N-cadherin, helps cancer cells to enter healthy tissue, while the other type, E-cadherin are incapable of breaking into the walls of healthy cells. The GC-4 antibody developed by Kim and Alber makes N-cadherin carrying cells to behave in the way of E-cadherin protein.
Researchers Focusing on Study of Blood Clots
Alber emphasizes on the criticality of stopping ovarian cancer from spreading, as the disease depicts few early symptoms, and is usually metastasized prior to its discovery. Alber and Kim are also focusing on research of blood clots, utilizing computer models for representing the formation of blood clots, and their impacts on health. When a blood vessel is injured, blood clots are formed, patching any disruption in the wall of vessel. When these clots get larger, they become capable of blocking blood vessels. Occurrence of such cases in the brain can result into a stroke. Pieces of clots may potentially cause embolism by breaking off into the bloodstream. While studying the mechanical stability of blood clots, Alber discerned at their composition, their interaction with one another, and how these interactions can affect the blood flow. The blood clot model’s development has been attributed to significant success in molecular imaging.
UCR has recently made the provision of a supercomputer lab, which is linked with many of the largest supercomputers across the globe. Alber and Kim look at the future in a way of cross-discipline collaborations, which they have utilized in their work. These researcher seem to be one step ahead in discovering an advanced method for stopping the propagation of ovarian cancer incidences. According to a latest study, the global ovarian cancer diagnostics market is expected to witness a steady rise. This further necessitates developments in drugs and treatment procedures for complete eradication of ovarian cancer.
Most popular reports
- Vacutainer Market, Forecast, Trend, Analysis & Competition Tracking - Global Market Insights 2021 to 2031
- Cardiac Patch Monitor Market - Global Industry Analysis 2016 - 2020 and Opportunity Assessment 2021 - 2031
- Arterial blood sampling systems market - Global Industry Analysis 2016 - 2020 and Opportunity Assessment 2021 - 2031